immuTide

immuTide is a preclinical-stage biotechnology company headquartered in Frankfurt, Germany, dedicated to developing a new class of peptide-based therapeutics. The company's core technology, the immuTide platform, enables the design of peptides that can effectively target infectious diseases and various forms of cancer. Their current pipeline includes candidates for COVID-19 and Influenza, which are designed to inhibit viral replication and boost the host's immune response. By focusing on peptides, immuTide seeks to overcome the limitations of large-molecule biologics, such as high production costs and complex delivery requirements. The company is actively progressing its lead programs through preclinical studies to support future clinical entry.